Small molecule · Inhibitor of ribonucleotide reductase and tubulin (TUBB) · developed by Relmada Therapeutics
NDV-01 is a sustained-release intravesical carbomer gel combining gemcitabine and docetaxel, released gradually into the bladder after catheter instillation. Gemcitabine is incorporated into DNA and inhibits ribonucleotide reductase, while docetaxel stabilizes tubulin, causing G2/M arrest. It is being studied in bladder urothelial carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07464145 | Phase 3 | Bladder (Urothelial, Transitional Cell) Cancer | Not yet recruiting | RLMD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Bladder (Urothelial, Transitional Cell) CancerUrologic CancerUrothelial Carcinoma BladderUrothelial Carcinoma Recurrent
Updated Nov 1, 2026. Something wrong or missing? Report it on the RLMD page.
See RLMD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RLMD catalysts and pipeline →